Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Stock Information for Q32 Bio Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Q32 Bio Inc Com

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
Leap Therapeutics Reports Second Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.